Methods and compositions for treating or preventing skin...

Details Methods and compositions for treating or preventing skin... Methods and compositions for treating or preventing skin...

2007-03-20

2007-03-20

Siew, Jeffrey (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S138100, C424S141100, C424S156100

Reexamination Certificate

active

10160506

ABSTRACT:
Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).

REFERENCES:
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4579844 (1986-04-01), Rovee et al.
patent: 4814275 (1989-03-01), Durda et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4863851 (1989-09-01), McEwan et al.
patent: 4863854 (1989-09-01), Mattes et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5013645 (1991-05-01), Kim
patent: 5053503 (1991-10-01), Dean et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5118611 (1992-06-01), Smith et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5198208 (1993-03-01), Berg et al.
patent: 5208324 (1993-05-01), Klaveness et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5314996 (1994-05-01), Wright, Jr.
patent: 5342924 (1994-08-01), Chang
patent: 5416064 (1995-05-01), Chari et al.
patent: 5419893 (1995-05-01), Berg et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5531978 (1996-07-01), Berg et al.
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5565562 (1996-10-01), Parker et al.
patent: 5578484 (1996-11-01), Horoszewicz
patent: 5599677 (1997-02-01), Dowell et al.
patent: 5639879 (1997-06-01), Mease et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5674470 (1997-10-01), Tweedle et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5935818 (1999-08-01), Israeli et al.
patent: 5958474 (1999-09-01), Lee et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6022524 (2000-02-01), Maisano et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6136311 (2000-10-01), Bander
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6168778 (2001-01-01), Janjic et al.
patent: 6200765 (2001-03-01), Murphy et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 0 208 531 (1987-01-01), None
patent: 0 232 751 (1987-08-01), None
patent: 0 233 619 (1987-08-01), None
patent: 0 279 397 (1988-08-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 299 795 (1989-01-01), None
patent: 0 315 188 (1989-05-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 392 423 (1990-10-01), None
patent: 0 466 200 AW (1992-01-01), None
patent: 0 495 878 (1992-07-01), None
patent: 0 594 739 (1994-05-01), None
patent: 0 882 454 AZ (1998-12-01), None
patent: WO 86/06384 (1986-11-01), None
patent: WO 88/02635 (1988-04-01), None
patent: WO 89/00557 (1989-01-01), None
patent: WO 89/06979 (1989-08-01), None
patent: WO 91/15466 (1991-10-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19668 (1993-10-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/26297 (1994-11-01), None
patent: WO 95/26206 (1995-10-01), None
patent: WO 95/31444 (1995-11-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 96/40245 (1996-12-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO98/03873 (1998-01-01), None
patent: WO 9803873 (1998-01-01), None
patent: WO 99/43710 (1999-09-01), None
patent: WO00/14257 (2000-03-01), None
patent: WO 00/50457 (2000-08-01), None
patent: WO 00/52473 (2000-09-01), None
patent: WO 00/74729 (2000-12-01), None
Li et al (Bioconjugate Chemistry, 5(2):101-104, Mar./Apr. 1994).
Koo (J. Dermatol. 1999; 26: 723-733).
Chang et al. (1999 ASCO Annual Meeting; Abs. No. 2399).
Auerbach et al. (Clinical Chemistry 2003, 49:1,32-40.
Jain et al. (Nat. Med. 1997, 3, 1203-1208).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3rd ed. 1993).
International Search Report, Jun. 6, 2003.
Barren et al. (1997), “Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells”, Prostate 30(1):65-8.
Carter et al. (1996), “Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase”, Proc. Natl. Acad. Sci. U.S.A. 93:749-751.
Chang et al. (1999), “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature”, Cancer Research, 59(13):3192-3198.
Diamond et al. (1997), “Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer”, Journal of Urology 157(4 suppl):226 (Abstract 884).
Dillman et al. (1988), “Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients”, Mol. Biother. 1(2):81-85.
Dillman et al. (1994), “Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies”, Cancer Biotherapy 9(1):17-28.
Fair et al. (1997), “Prostate Specific Membrane Antigen”, Prostate 32(2):140-8.
Goldsmith and Bander, “Monoclonal Antibody Therapy”, Nuclear Oncology: Diagnosis and Therapy. Chapter 32: Prostate Carcinoma. pp. 433-439. Lippincott Williams and Wilkins, Philadelphia, 2001.
Hamilton et al. (1998), “A novel humanized antibody against Prostate Specific Membrane Antigen (PSMA) for in vivo targeting and therapy”, Proc. Amer. Assoc. Cancer Res. 39:440, Abstract #2997.
Harlow and Lane (1988), “Antibodies: A laboratory manual”, Cold Spring Harbor Laboratory, p. 139-243.
Heston (1997), “Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase”, Urology 49(3A):104-112.
Holmes (2001), “PSMA specific antibodies and their diagnostic and therapeutic use”, Exp. Opin. Invest. Drugs 10(3):511-19.
Horoszewicz et al. (1987), “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients”, Anticancer Research 7(5B):927-936.
Israeli et al. (1993), “Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen”, Cancer Research 53(2):227-230.
Israeli et al. (1994), “Expression of the Prostate-Specific Membrane Antigen”, Cancer Research 54(7):1807-1811.
Israeli et al. (1997), “Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon”, Urological Clinics of North America 24(2):439-50.
Jain, R.K. (1990), “Vacular and interstitial barriers to delivery of therapeutic agents in tumors”, Cancer and Metastasis Reviews 9(3):253-266.
Leek et al. (1995), “Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene”, British Journal of Cancer 72:583-588.
Leung et al. (1986), “Selection of a Monoclonal Antibody to a New Prostate Cancer Marker for In Vivo Clinical Trials”, 6thInternational Congress of Immunology, p. 516 (Abstract 4.15.19).
Liu et al. (1997), “Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium”, Cancer Research 57(18):3629-3634.
Liu, et al. (1998), “Constitutive and Antib

Affiliated with

Also associated with

Rating

Methods and compositions for treating or preventing skin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating or preventing skin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating or preventing skin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3768005